In vitro model created that mimics chemoresistance in mantle cell lymphoma

Written by Jade Parker, Senior Editor

Researchers at the Carnegie Mellon University (PA, USA) have developed a novel clinically relevant in vitro model that mimics chemoresistance that is observed in mantle cell lymphoma (MCL) patients, an aggressive subtype of non-Hodgkin’s lymphoma. The findings were recently published in Experimental Biology and Medicine. The typical chemotherapy regimen administered to non-Hodgkin lymphoma patients – CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone) – has an effectiveness timeline of approximately 3 years, at which point patients no longer respond due to developed resistance. The development of chemoresistance in patients has limited the long-term success of CHOP, combined with the lack of in vitro...

To view this content, please register now for access

It's completely free